Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall.

Moyer AM, Yu J, Sinnwell JP, Dockter TJ, Suman VJ, Weinshilboum RM, Boughey JC, Goetz MP, Visscher DW, Wang L.

Oncotarget. 2019 Jun 11;10(39):3924-3930. doi: 10.18632/oncotarget.27001. eCollection 2019 Jun 11.

2.

Genes associated with bowel metastases in ovarian cancer.

Mariani A, Wang C, Oberg AL, Riska SM, Torres M, Kumka J, Multinu F, Sagar G, Roy D, Jung DB, Zhang Q, Grassi T, Visscher DW, Patel VP, Jin L, Staub JK, Cliby WA, Weroha SJ, Kalli KR, Hartmann LC, Kaufmann SH, Goode EL, Shridhar V.

Gynecol Oncol. 2019 Sep;154(3):495-504. doi: 10.1016/j.ygyno.2019.06.010. Epub 2019 Jun 14.

3.

Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy.

Al-Hilli Z, Choong G, Keeney MG, Visscher DW, Ingle JN, Goetz MP, Jakub JW.

Breast Cancer Res Treat. 2019 Aug;176(3):709-716. doi: 10.1007/s10549-019-05264-2. Epub 2019 May 22.

PMID:
31119569
4.

Hyaline fibrous involution of breast lobules: a histologic finding associated with germline BRCA mutation.

Lee HE, Arshad M, Brahmbhatt RD, Hoskin TL, Winham SJ, Frost MH, Radisky DC, Denison LA, Degnim AC, Visscher DW.

Mod Pathol. 2019 Sep;32(9):1263-1270. doi: 10.1038/s41379-019-0217-9. Epub 2019 Apr 17.

PMID:
30996252
5.

Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype.

Shieh Y, Scott CG, Jensen MR, Norman AD, Bertrand KA, Pankratz VS, Brandt KR, Visscher DW, Shepherd JA, Tamimi RM, Vachon CM, Kerlikowske K.

Breast Cancer Res. 2019 Apr 3;21(1):48. doi: 10.1186/s13058-019-1129-9.

6.

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH.

Gynecol Oncol. 2019 Apr;153(1):127-134. doi: 10.1016/j.ygyno.2019.01.015. Epub 2019 Jan 25.

PMID:
30686551
7.

Breast fibroadenomas are not associated with increased breast cancer risk in an African American contemporary cohort of women with benign breast disease.

Shaik AN, Ruterbusch JJ, Abdulfatah E, Shrestha R, Daaboul MHDF, Pardeshi V, Visscher DW, Bandyopadhyay S, Ali-Fehmi R, Cote ML.

Breast Cancer Res. 2018 Aug 9;20(1):91. doi: 10.1186/s13058-018-1027-6.

8.

Cellular fibroepithelial lesions of the breast: A long term follow up study.

Yasir S, Nassar A, Jimenez RE, Jenkins SM, Hartmann LC, Degnim AC, Frost M, Visscher DW.

Ann Diagn Pathol. 2018 Aug;35:85-91. doi: 10.1016/j.anndiagpath.2018.01.005. Epub 2018 Jan 10.

PMID:
30029048
9.

Evaluation of 2 breast cancer risk models in a benign breast disease cohort.

Frank RD, Winham SJ, Vierkant RA, Frost MH, Radisky DC, Ghosh K, Brandt KR, Sherman ME, Visscher DW, Hartmann LC, Degnim AC, Vachon CM.

Cancer. 2018 Aug;124(16):3319-3328. doi: 10.1002/cncr.31528. Epub 2018 Jun 22.

10.

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.

Yu J, Qin B, Moyer AM, Nowsheen S, Liu T, Qin S, Zhuang Y, Liu D, Lu SW, Kalari KR, Visscher DW, Copland JA, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Lou Z, Suman VJ, Weinshilboum R, Boughey JC, Goetz MP, Wang L.

J Clin Invest. 2018 Jun 1;128(6):2376-2388. doi: 10.1172/JCI97924. Epub 2018 Apr 30.

11.

Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia.

Degnim AC, Winham SJ, Frank RD, Pankratz VS, Dupont WD, Vierkant RA, Frost MH, Hoskin TL, Vachon CM, Ghosh K, Hieken TJ, Carter JM, Denison LA, Broderick B, Hartmann LC, Visscher DW, Radisky DC.

J Clin Oncol. 2018 Jun 20;36(18):1840-1846. doi: 10.1200/JCO.2017.75.9480. Epub 2018 Apr 20.

12.

Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.

Kalli KR, Block MS, Kasi PM, Erskine CL, Hobday TJ, Dietz A, Padley D, Gustafson MP, Shreeder B, Puglisi-Knutson D, Visscher DW, Mangskau TK, Wilson G, Knutson KL.

Clin Cancer Res. 2018 Jul 1;24(13):3014-3025. doi: 10.1158/1078-0432.CCR-17-2499. Epub 2018 Mar 15.

13.

Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics.

Rice MS, Tamimi RM, Bertrand KA, Scott CG, Jensen MR, Norman AD, Visscher DW, Chen YY, Brandt KR, Couch FJ, Shepherd JA, Fan B, Wu FF, Ma L, Collins LC, Cummings SR, Kerlikowske K, Vachon CM.

Breast Cancer Res Treat. 2018 Jul;170(1):129-141. doi: 10.1007/s10549-018-4735-9. Epub 2018 Mar 3.

14.

Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies.

Shen J, Hu Y, Putt KS, Singhal S, Han H, Visscher DW, Murphy LM, Low PS.

Oncotarget. 2017 Dec 15;9(4):4485-4495. doi: 10.18632/oncotarget.23321. eCollection 2018 Jan 12.

15.

Association between mammographic breast density and histologic features of benign breast disease.

Ghosh K, Vierkant RA, Frank RD, Winham S, Visscher DW, Pankratz VS, Scott CG, Brandt K, Sherman ME, Radisky DC, Frost MH, Hartmann LC, Degnim AC, Vachon CM.

Breast Cancer Res. 2017 Dec 19;19(1):134. doi: 10.1186/s13058-017-0922-6.

16.

Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.

Yu J, Qin B, Moyer AM, Sinnwell JP, Thompson KJ, Copland JA 3rd, Marlow LA, Miller JL, Yin P, Gao B, Minter-Dykhouse K, Tang X, McLaughlin SA, Moreno-Aspitia A, Schweitzer A, Lu Y, Hubbard J, Northfelt DW, Gray RJ, Hunt K, Conners AL, Suman VJ, Kalari KR, Ingle JN, Lou Z, Visscher DW, Weinshilboum R, Boughey JC, Goetz MP, Wang L.

Breast Cancer Res. 2017 Dec 6;19(1):130. doi: 10.1186/s13058-017-0920-8.

17.

Macrophagic "Crown-like Structures" Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease.

Carter JM, Hoskin TL, Pena MA, Brahmbhatt R, Winham SJ, Frost MH, Stallings-Mann M, Radisky DC, Knutson KL, Visscher DW, Degnim AC.

Cancer Prev Res (Phila). 2018 Feb;11(2):113-119. doi: 10.1158/1940-6207.CAPR-17-0245. Epub 2017 Nov 22.

18.

CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes.

Kerekes D, Visscher DW, Hoskin TL, Radisky DC, Brahmbhatt RD, Pena A, Frost MH, Arshad M, Stallings-Mann M, Winham SJ, Murphy L, Denison L, Carter JM, Knutson KL, Degnim AC.

Breast Cancer Res Treat. 2018 Feb;167(3):649-658. doi: 10.1007/s10549-017-4558-0. Epub 2017 Nov 1.

19.

Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.

Leon-Ferre RA, Polley MY, Liu H, Gilbert JA, Cafourek V, Hillman DW, Elkhanany A, Akinhanmi M, Lilyquist J, Thomas A, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Visscher DW, Goetz MP.

Breast Cancer Res Treat. 2018 Jan;167(1):89-99. doi: 10.1007/s10549-017-4499-7. Epub 2017 Sep 14.

20.

NanoString-based breast cancer risk prediction for women with sclerosing adenosis.

Winham SJ, Mehner C, Heinzen EP, Broderick BT, Stallings-Mann M, Nassar A, Vierkant RA, Hoskin TL, Frank RD, Wang C, Denison LA, Vachon CM, Frost MH, Hartmann LC, Aubrey Thompson E, Sherman ME, Visscher DW, Degnim AC, Radisky DC.

Breast Cancer Res Treat. 2017 Nov;166(2):641-650. doi: 10.1007/s10549-017-4441-z. Epub 2017 Aug 10.

21.

Epithelioid Inflammatory Myofibroblastic Sarcoma of the Ovary With RANB2-ALK Fusion: Report of a Case.

Fang H, Langstraat CL, Visscher DW, Folpe AL, Schoolmeester JK.

Int J Gynecol Pathol. 2018 Sep;37(5):468-472. doi: 10.1097/PGP.0000000000000431.

PMID:
28787324
22.

Postlactational involution biomarkers plasminogen and phospho-STAT3 are linked with active age-related lobular involution.

Stallings-Mann ML, Heinzen EP, Vierkant RA, Winham SJ, Hoskin TL, Denison LA, Nassar A, Hartmann LC, Visscher DW, Frost MH, Sherman ME, Degnim AC, Radisky DC.

Breast Cancer Res Treat. 2017 Nov;166(1):133-143. doi: 10.1007/s10549-017-4413-3. Epub 2017 Jul 27.

23.

Breast implant capsule-associated squamous cell carcinoma: a report of 2 cases.

Olsen DL, Keeney GL, Chen B, Visscher DW, Carter JM.

Hum Pathol. 2017 Sep;67:94-100. doi: 10.1016/j.humpath.2017.07.011. Epub 2017 Jul 22.

PMID:
28739500
24.

Breast cysts rapidly enlarging with replacement of breast parenchyma and asymmetry.

Al-Hilli Z, Javed A, Boughey JC, Lemaine V, Visscher DW, Pruthi S.

Breast J. 2018 Jan;24(1):83-85. doi: 10.1111/tbj.12839. Epub 2017 Jun 7. No abstract available.

PMID:
28590556
25.

Multivariate model to identify women at low risk of cancer upgrade after a core needle biopsy diagnosis of atypical ductal hyperplasia.

Peña A, Shah SS, Fazzio RT, Hoskin TL, Brahmbhatt RD, Hieken TJ, Jakub JW, Boughey JC, Visscher DW, Degnim AC.

Breast Cancer Res Treat. 2017 Jul;164(2):295-304. doi: 10.1007/s10549-017-4253-1. Epub 2017 May 4. Review.

PMID:
28474262
26.

Non-BRCA familial breast cancer: review of reported pathology and molecular findings.

Keeney MG, Couch FJ, Visscher DW, Lindor NM.

Pathology. 2017 Jun;49(4):363-370. doi: 10.1016/j.pathol.2017.03.002. Epub 2017 Apr 24. Review.

27.

Neuroendocrine Tumors of the Breast.

Visscher DW, Yasir S.

Endocr Pathol. 2017 Jun;28(2):121-127. doi: 10.1007/s12022-017-9477-4. Review.

PMID:
28389994
28.

Breast Cancer Risk and Progressive Histology in Serial Benign Biopsies.

Visscher DW, Frank RD, Carter JM, Vierkant RA, Winham SJ, Heinzen EP, Broderick BT, Denison LA, Allers TM, Johnson JL, Frost MH, Hartmann LC, Degnim AC, Radisky DC.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx035.

29.

Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.

Goetz MP, Kalari KR, Suman VJ, Moyer AM, Yu J, Visscher DW, Dockter TJ, Vedell PT, Sinnwell JP, Tang X, Thompson KJ, McLaughlin SA, Moreno-Aspitia A, Copland JA, Northfelt DW, Gray RJ, Hunt K, Conners A, Sicotte H, Eckel-Passow JE, Kocher JP, Ingle JN, Ellingson MS, McDonough M, Wieben ED, Weinshilboum R, Wang L, Boughey JC.

J Natl Cancer Inst. 2017 Jul 1;109(7). doi: 10.1093/jnci/djw306.

30.

Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort.

Vierkant RA, Degnim AC, Radisky DC, Visscher DW, Heinzen EP, Frank RD, Winham SJ, Frost MH, Scott CG, Jensen MR, Ghosh K, Manduca A, Brandt KR, Whaley DH, Hartmann LC, Vachon CM.

BMC Cancer. 2017 Jan 31;17(1):84. doi: 10.1186/s12885-017-3082-2.

31.

Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development.

Degnim AC, Hoskin TL, Arshad M, Frost MH, Winham SJ, Brahmbhatt RA, Pena A, Carter JM, Stallings-Mann ML, Murphy LM, Miller EE, Denison LA, Vachon CM, Knutson KL, Radisky DC, Visscher DW.

Clin Cancer Res. 2017 Jul 15;23(14):3945-3952. doi: 10.1158/1078-0432.CCR-16-2026. Epub 2017 Jan 26.

32.

Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients.

Mullooly M, Yang HP, Falk RT, Nyante SJ, Cora R, Pfeiffer RM, Radisky DC, Visscher DW, Hartmann LC, Carter JM, Degnim AC, Stanczyk FZ, Figueroa JD, Garcia-Closas M, Lissowska J, Troester MA, Hewitt SM, Brinton LA, Sherman ME, Gierach GL.

Breast Cancer Res. 2017 Jan 19;19(1):8. doi: 10.1186/s13058-016-0791-4.

33.

Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast.

Bodelon C, Oh H, Chatterjee N, Garcia-Closas M, Palakal M, Sherman ME, Pfeiffer RM, Geller B, Vacek P, Weaver DL, Chicoine R, Papathomas D, Xiang J, Patel DA, Khodr ZG, Linville L, Clare SE, Visscher DW, Mies C, Hewitt SM, Brinton LA, Storniolo AMV, He C, Chanock SJ, Gierach GL, Figueroa JD.

Int J Cancer. 2017 Feb 15;140(4):825-832. doi: 10.1002/ijc.30512. Epub 2016 Nov 18.

34.

Mott cell (Russell body) Barrett's esophagitis.

Rangan A, Visscher DW.

Blood. 2016 Oct 13;128(15):1992. No abstract available.

35.

The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.

Li Z, Block MS, Vierkant RA, Fogarty ZC, Winham SJ, Visscher DW, Kalli KR, Wang C, Goode EL.

Tumour Biol. 2016 Oct;37(10):13279-13286. doi: 10.1007/s13277-016-5163-2. Epub 2016 Jul 26.

36.

Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women.

Degnim AC, Dupont WD, Radisky DC, Vierkant RA, Frank RD, Frost MH, Winham SJ, Sanders ME, Smith JR, Page DL, Hoskin TL, Vachon CM, Ghosh K, Hieken TJ, Denison LA, Carter JM, Hartmann LC, Visscher DW.

Cancer. 2016 Oct;122(19):2971-8. doi: 10.1002/cncr.30153. Epub 2016 Jun 28.

37.

Breast cancer risk by the extent and type of atypical hyperplasia.

Degnim AC, Visscher DW, Radisky DC, Frost MH, Vierkant RA, Frank RD, Winham SJ, Vachon CM, Dupont WD, Hartmann LC.

Cancer. 2016 Oct;122(19):3087-8. doi: 10.1002/cncr.30151. Epub 2016 Jun 28. No abstract available.

38.

Ages at menarche- and menopause-related genetic variants in relation to terminal duct lobular unit involution in normal breast tissue.

Oh H, Bodelon C, Palakal M, Chatterjee N, Sherman ME, Linville L, Geller BM, Vacek PM, Weaver DL, Chicoine RE, Papathomas D, Patel DA, Xiang J, Clare SE, Visscher DW, Mies C, Hewitt SM, Brinton LA, Storniolo AM, He C, Garcia-Closas M, Chanock SJ, Gierach GL, Figueroa JD.

Breast Cancer Res Treat. 2016 Jul;158(2):341-50. doi: 10.1007/s10549-016-3859-z. Epub 2016 Jun 24.

39.

Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes.

Purrington KS, Visscher DW, Wang C, Yannoukakos D, Hamann U, Nevanlinna H, Cox A, Giles GG, Eckel-Passow JE, Lakis S, Kotoula V, Fountzilas G, Kabisch M, Rüdiger T, Heikkilä P, Blomqvist C, Cross SS, Southey MC, Olson JE, Gilbert J, Deming-Halverson S, Kosma VM, Clarke C, Scott R, Jones JL, Zheng W, Mannermaa A; Jane Carpenter for ABCTC Investigators, Eccles DM, Vachon CM, Couch FJ.

Breast Cancer Res Treat. 2016 May;157(1):117-31. doi: 10.1007/s10549-016-3775-2. Epub 2016 Apr 15.

40.

Natural history of age-related lobular involution and impact on breast cancer risk.

Radisky DC, Visscher DW, Frank RD, Vierkant RA, Winham S, Stallings-Mann M, Hoskin TL, Nassar A, Vachon CM, Denison LA, Hartmann LC, Frost MH, Degnim AC.

Breast Cancer Res Treat. 2016 Feb;155(3):423-30. doi: 10.1007/s10549-016-3691-5. Epub 2016 Feb 4.

41.

Mucocele-like lesions of the breast: a clinical outcome and histologic analysis of 102 cases.

Meares AL, Frank RD, Degnim AC, Vierkant RA, Frost MH, Hartmann LC, Winham SJ, Visscher DW.

Hum Pathol. 2016 Mar;49:33-8. doi: 10.1016/j.humpath.2015.10.004. Epub 2015 Oct 31.

42.

Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).

Yoon HH, Foster NR, Meyers JP, Steen PD, Visscher DW, Pillai R, Prow DM, Reynolds CM, Marchello BT, Mowat RB, Mattar BI, Erlichman C, Goetz MP.

Ann Oncol. 2016 Feb;27(2):339-44. doi: 10.1093/annonc/mdv543. Epub 2015 Nov 16.

43.

Clinicopathologic features of breast cancers that develop in women with previous benign breast disease.

Visscher DW, Frost MH, Hartmann LC, Frank RD, Vierkant RA, McCullough AE, Winham SJ, Vachon CM, Ghosh K, Brandt KR, Farrell AM, Tarabishy Y, Hieken TJ, Haddad TC, Kraft RA, Radisky DC, Degnim AC.

Cancer. 2016 Feb 1;122(3):378-85. doi: 10.1002/cncr.29766. Epub 2015 Oct 29.

44.

Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy.

Ellingson MS, Hart SN, Kalari KR, Suman V, Schahl KA, Dockter TJ, Felten SJ, Sinnwell JP, Thompson KJ, Tang X, Vedell PT, Barman P, Sicotte H, Eckel-Passow JE, Northfelt DW, Gray RJ, McLaughlin SA, Moreno-Aspitia A, Ingle JN, Moyer AM, Visscher DW, Jones K, Conners A, McDonough M, Wieben ED, Wang L, Weinshilboum R, Boughey JC, Goetz MP.

Breast Cancer Res Treat. 2015 Sep;153(2):435-43. doi: 10.1007/s10549-015-3545-6. Epub 2015 Aug 22.

45.

ERβ expression and breast cancer risk prediction for women with atypias.

Hieken TJ, Carter JM, Hawse JR, Hoskin TL, Bois M, Frost M, Hartmann LC, Radisky DC, Visscher DW, Degnim AC.

Cancer Prev Res (Phila). 2015 Nov;8(11):1084-92. doi: 10.1158/1940-6207.CAPR-15-0198. Epub 2015 Aug 14.

46.

Complex fibroadenoma and breast cancer risk: a Mayo Clinic Benign Breast Disease Cohort Study.

Nassar A, Visscher DW, Degnim AC, Frank RD, Vierkant RA, Frost M, Radisky DC, Vachon CM, Kraft RA, Hartmann LC, Ghosh K.

Breast Cancer Res Treat. 2015 Sep;153(2):397-405. doi: 10.1007/s10549-015-3535-8. Epub 2015 Aug 12.

47.

Gene signature model for breast cancer risk prediction for women with sclerosing adenosis.

Degnim AC, Nassar A, Stallings-Mann M, Keith Anderson S, Oberg AL, Vierkant RA, Frank RD, Wang C, Winham SJ, Frost MH, Hartmann LC, Visscher DW, Radisky DC.

Breast Cancer Res Treat. 2015 Aug;152(3):687-94. doi: 10.1007/s10549-015-3513-1. Epub 2015 Jul 23.

48.

Assessment of folate receptor-β expression in human neoplastic tissues.

Shen J, Putt KS, Visscher DW, Murphy L, Cohen C, Singhal S, Sandusky G, Feng Y, Dimitrov DS, Low PS.

Oncotarget. 2015 Jun 10;6(16):14700-9.

49.

Ki-67 expression in sclerosing adenosis and adjacent normal breast terminal ductal lobular units: a nested case-control study from the Mayo Benign Breast Disease Cohort.

Nassar A, Hoskin TL, Stallings-Mann ML, Degnim AC, Radisky DC, Frost MH, Vierkant RA, Hartmann LC, Visscher DW.

Breast Cancer Res Treat. 2015 May;151(1):89-97. doi: 10.1007/s10549-015-3370-y. Epub 2015 Apr 12.

50.

Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.

Geels YP, van der Putten LJ, van Tilborg AA, Lurkin I, Zwarthoff EC, Pijnenborg JM, van den Berg-van Erp SH, Snijders MP, Bulten J, Visscher DW, Dowdy SC, Massuger LF.

Gynecol Oncol. 2015 May;137(2):245-51. doi: 10.1016/j.ygyno.2015.03.007. Epub 2015 Mar 12.

PMID:
25773202

Supplemental Content

Loading ...
Support Center